Pioneers in the Field of
Cardiac Gene Therapy
Why Sardocor
A UNIQUE APPROACH TO
CARDIAC GENE THERAPY
A UNIQUE APPROACH TO
CARDIAC GENE THERAPY
Sardocor has obtained open Investigational New Drug (IND) approvals from The United States Food and Drug Administration (FDA) for three gene therapy clinical trials.
Pioneering Delivery
> 1,000 doses of SRD001 have been manufactured and been made available to patients.
Our proprietary intracoronary delivery method to infuse gene therapy drug right into the heart has been uniquely designed to use the least amount drugs for efficacy while avoiding side effects.
Investors
JOIN A GROUP OF
REVOLUTIONARY STARTERS
Sardocor is on the lookout for investor relationships that can mutually benefit
our science, propel innovation and investment.
Sardocor strives to improve the quality of life in patients afflicted with incurable diseases with next-generation cell and gene therapy.
2024 All Rights Reserved | Sardocor, a division of Medera